A new high-dose weight-loss injection has moved a step closer to wider use in the UK.

The UK’s MHRA is the first regulatory agency to approve the high-dose Wegovy regimen.

Novo Nordisk’s Wegovy (semaglutide injection) has received a new approval from the Medicines and Healthcare products ...

Chief Safety Officer at the MHRA comments on new Lancet review, which found no increased risk of autism, ADHD, or ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled COPD of an eosinophilic phenotype who are already receiving triple therapy ...

GLP-1 agonist injections, although originally developed to treat type 2 diabetes, have changed how we approach obesity.1 The two main types now in use—semaglutide (Wegovy), produced by Novo Nordisk, ...

The new rules introduce a fast-track notification route, enabling quicker starts for lower-risk trials and maintaining safety ...

The MHRA has strengthened addiction warnings for Z-drugs, benzodiazepines, and gabapentinoids after a review found risks of dependence and withdrawal.

Great Britain is entering a new era of MedTech regulation, with major pre-market changes expected that are designed to ...